Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. weekly Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E8.05 EPS (ttm)34.14 Insider Own0.20% Shs Outstand160.60M Perf Week0.87%
Market Cap43.51B Forward P/E8.66 EPS next Y31.71 Insider Trans-0.76% Shs Float157.07M Perf Month3.75%
Income5.93B PEG- EPS next Q8.26 Inst Own94.40% Short Float1.77% Perf Quarter-6.28%
Sales14.49B P/S3.00 EPS this Y44.80% Inst Trans0.26% Short Ratio1.82 Perf Half Y2.17%
Book/sh70.42 P/B3.90 EPS next Y-10.48% ROA22.30% Target Price300.54 Perf Year13.01%
Cash/sh27.32 P/C10.05 EPS next 5Y-1.37% ROE46.30% 52W Range215.77 - 374.99 Perf YTD-7.43%
Dividend- P/FCF6.40 EPS past 5Y20.50% ROI30.50% 52W High-26.75% Beta0.56
Dividend %- Quick Ratio2.20 Sales past 5Y8.20% Gross Margin88.00% 52W Low27.30% ATR7.05
Employees7400 Current Ratio2.50 Sales Q/Q1.80% Oper. Margin50.90% RSI (14)44.87 Volatility2.39% 2.25%
OptionableYes Debt/Eq0.66 EPS Q/Q22.10% Profit Margin40.90% Rel Volume0.84 Prev Close274.86
ShortableYes LT Debt/Eq0.66 EarningsJul 22 BMO Payout0.00% Avg Volume1.53M Price274.69
Recom2.80 SMA20-1.14% SMA50-2.80% SMA200-7.03% Volume1,288,904 Change-0.06%
Jul-27-20Upgrade Morgan Stanley Underweight → Overweight $263 → $357
Jun-22-20Reiterated RBC Capital Mkts Sector Perform $303 → $273
Jun-22-20Downgrade Barclays Overweight → Equal Weight $370 → $280
Jun-09-20Downgrade Bernstein Outperform → Mkt Perform $360 → $297
Apr-23-20Downgrade Raymond James Mkt Perform → Underperform
Apr-23-20Downgrade Citigroup Neutral → Sell $365 → $240
Mar-31-20Initiated Wolfe Research Peer Perform
Feb-27-20Initiated Barclays Overweight $389
Jan-27-20Upgrade Canaccord Genuity Hold → Buy $360
Dec-13-19Upgrade Credit Suisse Underperform → Neutral $260 → $300
Dec-02-19Downgrade Robert W. Baird Neutral → Underperform
Nov-12-19Initiated SunTrust Buy $337
Nov-01-19Downgrade Standpoint Research Buy → Hold
Oct-30-19Upgrade Bernstein Mkt Perform → Outperform
Oct-23-19Upgrade SVB Leerink Mkt Perform → Outperform $256 → $350
Oct-23-19Upgrade Guggenheim Neutral → Buy $256 → $365
Oct-23-19Reiterated H.C. Wainwright Buy $300 → $335
Oct-23-19Reiterated BofA/Merrill Underperform $200 → $235
Oct-17-19Resumed BofA/Merrill Underperform $200
Jun-28-19Downgrade Piper Jaffray Overweight → Neutral $280 → $250
Jul-28-20 03:18PM  
11:11AM  
Jul-27-20 01:48PM  
12:39PM  
10:20AM  
10:09AM  
07:49AM  
04:09AM  
01:54AM  
Jul-25-20 10:01AM  
Jul-24-20 06:43PM  
04:06PM  
Jul-23-20 02:35PM  
01:08PM  
12:07PM  
08:00AM  
Jul-22-20 04:30PM  
04:24PM  
02:20PM  
01:01PM  
11:35AM  
10:25AM  
09:43AM  
09:02AM  
08:41AM  
07:30AM  
07:24AM  
07:13AM  
07:01AM  
Jul-21-20 06:38PM  
06:12PM  
06:00PM  
11:54AM  
07:50AM  
07:30AM  
Jul-20-20 08:24AM  
Jul-16-20 04:25PM  
01:26PM  
10:31AM  
Jul-15-20 05:55PM  
Jul-14-20 10:15AM  
08:30AM  
07:37AM  
Jul-13-20 07:31PM  
Jul-10-20 08:37PM  
08:23AM  
Jul-09-20 08:11AM  
08:09AM  
05:06AM  
03:35AM  
12:23AM  
Jul-08-20 11:46PM  
06:15PM  
04:31PM  
04:24PM  
04:01PM  
03:59PM  
03:37PM  
03:35PM  
02:42PM  
01:10PM  
01:04PM  
11:25AM  
11:18AM  
10:36AM  
10:34AM  
10:13AM  
09:15AM  
08:44AM  
08:40AM  
07:30AM  
07:27AM  
Jul-06-20 06:25PM  
Jul-02-20 05:30PM  
04:51PM  
09:00AM  
Jul-01-20 07:37AM  
Jun-30-20 04:26PM  
11:18AM  
Jun-29-20 10:49AM  
Jun-22-20 04:56PM  
12:04PM  
10:29AM  
Jun-20-20 09:48AM  
Jun-19-20 06:43PM  
06:04PM  
11:00AM  
10:22AM  
09:34AM  
Jun-18-20 09:40PM  
06:52PM  
05:53PM  
04:46PM  
04:21PM  
02:19PM  
01:31PM  
12:24PM  
11:55AM  
11:08AM  
11:02AM  
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHERWIN STEPHEN ADirectorMar 11Option Exercise58.4612,278717,77216,517Mar 12 06:56 PM
SHERWIN STEPHEN ADirectorMar 11Sale295.222,434718,57414,353Mar 12 06:56 PM
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.004,847033,775Feb 19 06:20 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 15Option Exercise0.001,213015,019Feb 19 06:17 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.0044102,672Feb 19 06:13 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 15Option Exercise0.001,553037,261Feb 19 06:09 PM
Kramer RobinVP, Chief Accounting OfficerFeb 12Option Exercise0.001320282Feb 14 06:37 PM
Karp DanielEVP, Corporate DevelopmentFeb 12Option Exercise0.0096001,224Feb 14 06:36 PM
Guindo ChirfiEVP Glob. Prod Strat and CommFeb 12Option Exercise0.001,68004,375Feb 14 06:34 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.003,54705,021Feb 14 06:32 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.001,15402,337Feb 14 06:30 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerFeb 12Option Exercise0.001,91903,732Feb 14 06:27 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 12Option Exercise0.005,967036,389Feb 14 06:25 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.0011,994031,483Feb 14 06:19 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 12Option Exercise0.005,216014,509Feb 14 06:16 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerJan 02Option Exercise0.001,30202,219Jan 06 04:14 PM
Kramer RobinVP, Chief Accounting OfficerDec 03Option Exercise0.00840175Dec 05 04:24 PM
Posner Brian SDirectorDec 02Sale292.351,055308,4296,995Dec 03 05:58 PM
Guindo ChirfiEVP Glob. Prod Strat and CommDec 01Option Exercise0.0054302,855Dec 03 05:59 PM